胃癌靶向治疗.PPT
- 文档编号:1225458
- 上传时间:2022-10-19
- 格式:PPT
- 页数:65
- 大小:5.10MB
胃癌靶向治疗.PPT
《胃癌靶向治疗.PPT》由会员分享,可在线阅读,更多相关《胃癌靶向治疗.PPT(65页珍藏版)》请在冰豆网上搜索。
张俊上海交通大学医学院附属瑞金医院外科,胃癌分子靶向治疗的若干热点问题,分子靶向治疗困惑的临床,理解分子靶点理解疗效与特异性毒性反应药物机理与临床研究结果的解读分子靶向治疗药物的应用实践做到真正的translationalresearch指导临床研究设计指导临床指南,近十年的晚期胃癌临床研究,MAGICinNEJM(Cunningham,2006)TAX325inJCO(EricVanCutsem,2006)REAL-2inNEJM(Cunningham,2008)ML-17032inAnnOncology(Kang,2009)FLAGSinASCOGI(Ajani,2009)ToGAinASCO(EricVanCutsem&Bang,2009)AVAGASTinASCO(Kang,2010)GRANIT-1(EricVanCutsem,2012)REAL-3(Waddell,2012),目前正在研究中的胃癌治疗靶点与靶向药物,WongH,YauT.TheOncologist2012;17:
346-358.,合理治疗靶点的标准,与肿瘤的恶性表型相关重要脏器与组织中很少表达分子特性与生物学行为相关能在临床较易获得的样本中重复检测与临床预后相关当该靶点被阻断、干扰或抑制时,对高度表达该靶点的患者应有一定的临床反应,对不表达该靶点者,应无或产生较少临床反应,胃癌的分子靶点寻找,KRASMT40%)HER-2过表达10-25%,单药应用疗效有限(Phase2),靶向化疗:
成绩较好(Phase2),1.Shahetal.JClinOncol,2006;24;6201;2.DLFabioetal.ESMO,2006,Abstract1077PD;3.Pintoetal.AnnOncol2007;4.Lordicketal.AnnOncol2008,铂类药物替换,氟尿嘧啶类药物替换,分子靶向药物,添加药物,替换药物,基于优效性检验的胃癌一线化疗方案,晚期胃癌药物治疗的优化策略,序贯治疗,诱导化疗/维持化疗,其他策略,目标:
延长生存,ToGA(XP/FPH),AVAGAST(XPBV),07/23/2007,胃癌EGFR表达,包括EGF家族在内的各类生长因子及其受体在胃癌中呈过度表达(GastricCancer2004;7:
61-77)免疫组化染色提示胃癌组织中EGFR表达率为59,586%(JCO2006;24:
4922-4927;ASCO2007#4526)RT-PCR检测提示胃癌组织中EGFR基因扩增率约62%(WorldJGastroenterol2007;13:
3605-3609)EGFR表达升高与以下临床病理因素相关:
进展期胃癌淋巴结转移生存期缩短(EJC2001;37:
S9-S15),EGFreceptorsignalingpathway:
Arationaleforpersonalizedtherapy,YardenY,SliwkowskiMX.NatRevMolCellBiol2001;2:
127137;ChakravartiA,etal.CancerRes2002;62:
43074315;BaselgaJ.EurJCancer2001;37(Suppl.4):
S16S22;KawanakaH,etal.LifeSci2001;69:
30193033,EGFRTKIinGC(Phase2),Doi2036,ProcASCO22,2003;FerryClinCanRes,132:
5669,2007,Jarmaat,JCO,24,2008,07/23/2007,西妥昔单抗一线治疗胃癌的尝试,年龄18岁,KPS评分60分病理学和/或细胞学证实为胃腺癌,预计生存期3月局部晚期或转移性癌,无法手术切除一线治疗患者,接受辅助治疗至少间隔6月以上血常规检查正常:
WBC3.0109/L,中性粒细胞1.5109/L,PLT80109/LECOG评分为2无严重心、肺、肝、肾功能障碍,未伴发急性感染,西妥昔单抗+FOLFOX4一线治疗晚期胃癌临床观察,ShiM,ZhangJ,etal,Hepatogastroenterology,2011,临床疗效评价,例数百分比(%),CR00,PD416.0,SD1248.0,PR936.0,ORR=9/25=36.0%DCR=20/24=84.0%,ShiM,ZhangJ,etal,Hepatogastroenterology,2011,治疗前后CT,病例1:
胃癌肝转移,ShiM,ZhangJ,etal,Hepatogastroenterology,2011,治疗前后CT,病例2:
胃癌肝多发转移,ShiM,ZhangJ,etal,Hepatogastroenterology,2011,治疗前后CT,病例3:
胃癌肝多发转移,ShiM,ZhangJ,etal,Hepatogastroenterology,2011,PFS&OS,mPFS=6.5个月,mOS=10.6个月,ShiM,ZhangJ,etal,Hepatogastroenterology,2011,胃癌KRAS突变率,KRASrecentlyidentifiedaspredictivemarkerforresponsetoEGFR-inhibitortherapyinmCRC.IncidenceofKRASmutationsingastriccancer?
Currentassumption:
KRAS尚不能作为胃癌EGFR靶向抑制治疗的疗效预测标志物,Cisplatin80mg/m2d1Capecitabine1000mg/m2twicedaily;d1-14q3w,RANDOM,UntilradiographicallydocumentedPDorunacceptabletoxicityPrimaryendpoint:
PFStime(asassessedbyIndependentReviewCommittee),Cisplatin80mg/m2d1Capecitabine1000mg/m2twicedaily;d1-14q3wCetuximab400mg/m2loadingdose,then250mg/m2perweek,EXPANDPhaseIII,EGFR单克隆抗体的分类,-momab,-ximab,-mumab,-zumab,鼠源,嵌合,全人源化,人源化,如何改进?
进行亲和力设计,实现最适亲和力,TITLE,TITLE,TITLE,TITLE,皮疹与疗效相关?
ToGA研究中HER-2检测情况,HER2withIHC&FISHResults2484个进展期胃癌蜡块544HER2+(21,9%)IHC-FISH一致率87,3与胃癌临床病理因素的关系,HER-2在胃癌表达,AnnOncol,2008,19:
1523外科杂志1996,1:
25,宫立群133中国18,1IHC,ToGA研究设计,HER2-阳性晚期胃癌患者(n=584),5-FU或卡培他滨a+顺铂(n=290),R,a由研究者的判别来选择GEJ,胃食管连接部,5-FU或卡培他滨a+顺铂+赫赛汀(n=294),分层因素局部晚期或转移性胃体部vs胃食管连接部可测量vs不可测量ECOG评分0-1vs2卡培他滨vs5-FU,全球、多中心、随机、开放III期临床研究,1Bangetal;Abstract4556,ASCO2009,3807位患者接受筛选1810HER2-阳性(22.1%),患者的人口统计学以及基线特征,入组最多的为韩国,日本,中国和俄罗斯F,氟尿嘧啶;C,顺铂an=287;bn=293,Primaryendpoint:
OS,Time(months),294290,277266,246223,209185,173143,147117,11390,9064,7147,5632,4324,3016,2114,137,126,65,40,10,00,No.atrisk,11.1,13.8,0.0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1.0,0,2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,Event,FC+T,FC,Events167182,HR0.74,95%CI0.60,0.91,pvalue0.0046,MedianOS13.811.1,T,trastuzumab,Secondaryendpoint:
PFS,0,2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,Event,294290,258238,201182,14199,9562,6033,4117,287,215,133,93,82,62,61,61,40,20,00,5.5,6.7,No.atrisk,0.0,0.1,0.2,0.3,0.4,0.5,0.6,0.7,0.8,0.9,1.0,Time(months),FC+T,FC,Events226235,HR0.71,95%CI0.59,0.85,pvalue0.0002,MedianPFS6.75.5,Secondaryendpoint:
tumorresponserate,2.4%,5.4%,32.1%,41.8%,34.5%,47.3%,Intenttotreat,ORR=CR+PRCR,completeresponse;PR,partialresponse,p=0.0599,p=0.0145,F+C+trastuzumab,F+C,p=0.0017,Patients(%),CR,PR,ORR,Cross-trialComparationof1stTxofGC,张俊,中国医学论坛报,20090723,TheresponserateofHerceptin+CTinHER-2positivepatientswas47.3%,whichmeanstheotherhalfofthepatientswerenoresponsetoHerceptintreatmentTheunderlyingmechanismisstillunclear,Comments(Responserate),TITLE,标本储藏条件对IHC和FISH结果的影响胃癌的异质性胃癌细胞HER-2染色特征与乳腺癌的差异,Comments(StandardtechniquesforHER-2detection),Comments(Predictivemarker),HER-2与胃癌预后不良相关,HER-2作为Herceptin治疗胃癌的疗效预测标志物的价值?
HER-2/neu信号通路内的其他接头蛋白或转录因子作为潜在疗效预测标志物的价值?
EGFR单抗治疗中KRAS的故事,113,OSinIHC2+/FISH+orIHC3+(exploratoryanalysis),1.0,0.8,0.6,0.4,0.2,0.0,36,34,32,30,28,26,24,22,20,18,16,14,12,10,8,6,4,2,0,Time(months),11.8,16.0,FC+T,FC,Events120136,HR0.65,95%CI0.51,0.83,MedianOS16.011.8,Event,0.1,0.3,0.5,0.
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 胃癌 靶向 治疗
![提示](https://static.bdocx.com/images/bang_tan.gif)